Aquestive Therapeutics Inc (NASDAQ:AQST) has a beta value of 2.67 and has seen 2.47 million shares traded in the last trading session. The company, currently valued at $351.03M, closed the last trade at $3.85 per share which meant it gained $0.25 on the day or 6.94% during that session. The AQST stock price is -61.82% off its 52-week high price of $6.23 and 52.21% above the 52-week low of $1.84. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.64 million shares traded. The 3-month trading volume is 1.48 million shares.
The consensus among analysts is that Aquestive Therapeutics Inc (AQST) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.13.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Sporting 6.94% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the AQST stock price touched $3.85 or saw a rise of 1.53%. Year-to-date, Aquestive Therapeutics Inc shares have moved 90.59%, while the 5-day performance has seen it change 0.79%. Over the past 30 days, the shares of Aquestive Therapeutics Inc (NASDAQ:AQST) have changed -13.29%. Short interest in the company has seen 10.15 million shares shorted with days to cover at 6.37.
Wall Street analysts have a consensus price target for the stock at $10, which means that the shares’ value could jump 61.5% from current levels. The projected low price target is $10.0 while the price target rests at a high of $10.0. In that case, then, we find that the current price level is -159.74% off the targeted high while a plunge would see the stock gain -159.74% from current levels.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
Figures show that Aquestive Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 43.66% over the past 6 months, with this year growth rate of -246.15%, compared to 16.50% for the industry. Revenue growth from the last financial year stood is estimated to be 13.38%.
8 analysts offering their estimates for the company have set an average revenue estimate of 13.13M for the current quarter. 5 have an estimated revenue figure of 13.08M for the next ending quarter. Year-ago sales stood 13.21M and 12.05M respectively for this quarter and the next, and analysts expect sales will shrink by -0.60% for the current quarter and 13.38% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 46.61% over the past 5 years.
AQST Dividends
Aquestive Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders
Insiders own 5.01% of the company shares, while shares held by institutions stand at 55.98% with a share float percentage of 58.93%. Investors are also buoyed by the number of investors in a company, with Aquestive Therapeutics Inc having a total of 151.0 institutions that hold shares in the company. The top two institutional holders are BRATTON CAPITAL MANAGEMENT, L.P. with over 9.81 million shares worth more than $25.51 million. As of 2024-06-30, BRATTON CAPITAL MANAGEMENT, L.P. held 13.3274% of shares outstanding.
The other major institutional holder is VR ADVISER, LLC, with the holding of over 5.56 million shares as of 2024-06-30. The firm’s total holdings are worth over $14.44 million and represent 7.5468% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Sep 30, 2024 , the former fund manager holds about 2.64% shares in the company for having 2.4 shares of worth $9.26 million while later fund manager owns 1.94 shares of worth $7.48 million as of Sep 30, 2024 , which makes it owner of about 2.13% of company’s outstanding stock.
